Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium [99mtc] isonitrile glucosamine
- Development stage
- Phase 2
- Lead developer
- Beijing Shihong Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium [99mTc] isonitrile glucosamine (99mTc-CNDG7) is a radiopharmaceutical diagnostic imaging agent developed by Beijing Shihong Pharmaceutical. It is designed for use with SPECT/CT imaging to detect regional lymph node metastasis in patients with confirmed or suspected non-small cell lung cancer (NSCLC). The agent consists of a technetium-99m isotope complexed with an isonitrile-functionalized glucosamine moiety. As a radiolabeled glucose analog, it is taken up by metabolically active tumor cells, likely via glucose transporters (GLUT) which are overexpressed in malignant tissues. This allows for the visualization and localization of metastatic lymph nodes, aiding in the staging and surgical planning for NSCLC patients. It is currently being evaluated in Phase II clinical trials in China.
- Other names
- technetium [99mTc] isonitrile glucosamine99mTc-isonitrile glucosamine
02
Targets
SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)
Beyond the preview
Go deeper on technetium [99mtc] isonitrile glucosamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium [99mtc] isonitrile glucosamine.